**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 57078

**Manuscript Type:** CASE REPORT

**Primary rhabdomyosarcoma: An extremely rare and aggressive variant of male breast cancer**

Satală CB *et al*. Mammary rhabdomyosarcoma

Cătălin Bogdan Satală, Ioan Jung, Tivadar Jr Bara, Patricia Simu, Iunius Simu, Madalina Vlad, Rita Szodorai, Simona Gurzu

**Cătălin Bogdan Satală,** Department of Pathology, Clinical County Emergency Hospital, Tirgu Mures 540139, Romania

**Ioan Jung, Rita Szodorai,** Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology, Targu Mures 530149, Romania

**Tivadar Jr Bara,** Department of Surgery, Clinical County Emergency Hospital, Targu Mures 540136, Romania

**Patricia Simu, Iunius Simu,** Department of Radiology, George Emil Palade University of Medicine, Pharmacy, Sciences and Technology, Targu Mures 530149, Romania

**Madalina Vlad, Simona Gurzu,** Department of Pathology, Clinical County Emergency Hospital, Targu Mures 540136, Romania

**Simona Gurzu,** Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures 530149, Romania

**Simona Gurzu,** Research Center (CCAMF), University of Medicine, Pharmacy, Sciences and Technology, Targu Mures 540139, Romania

**Author contributions:** Satală CB drafted the article, searched for the literature and contributed to the diagnosis; Jung I contributed to the diagnosis and immunohistochemical assessment; Bara TJ performed the surgical intervention and clinical follow-up; Simu P and Simu I contributed to the diagnosis with the imaging assessment and literature data review; Vlad M performed the macroscopic assessment and contributed to the histological diagnosis; Szodorai R was involved in literature review; Gurzu S supervised the histological and immunohistochemical diagnosis and conferred the final agreement for publication; Satala CB and Jung I have equal contribution to the paper.

**Corresponding author: Simona Gurzu, MD, PhD, Chief Doctor, Dean, Director, Full Professor, Research Scientist,** Department of Pathology, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 38 Gheorghe Marinescu Street, Targu Mures 530149, Romania. simonagurzu@yahoo.com

**Received:** May 24, 2020

**Revised:** July 28, 2020

**Accepted:** September 4, 2020

**Published online:** October 6, 2020

**Abstract**

BACKGROUND

Rhabdomyosarcoma (RMS) of the breast, a mesenchymal neoplasm with skeletal muscle differentiation, is an extremely rare tumour in males, with less than 30 cases published in English-language literature. We report on the first case of a male breast RMS, with an unusual ectomesenchymal/neuroectodermal component.

CASE SUMMARY

A 55-year-old, previously healthy male, underwent a radical left mastectomy for an ulcerated tumour mass, occupying the breast and left anterior thoracic wall. The biopsy specimen indicated the presence of a tumour with neural origins, namely a peripheral neuroectodermal tumour (PNET). The surgical specimens identified two components. The rhabdomyosarcomatous component (over 70%) was represented by large pleomorphic cells with positivity for desmin, sarcomeric actin and myogenin. The PNET-like ectomesenchymal component, which was admixed with the RMS cells, and was also revealed during the preoperative biopsy, consisted of small cells which expressed neurofilament, neuron specific enolase and CD99. The microscopic examination, along with the immunohistochemical profile, allowed the diagnosis of an RMS, with unusual ectomesenchymal differentiation. The patient refused the postoperative oncologic therapy and died three months after surgery.

CONCLUSION

In patients withRMS of the breast, the PNET-like ectomesenchymal component increases the diagnosis difficulty, especially in biopsy specimens. This differentiation can be immunohistochemically proven and might highlight the possible development of high-grade sarcoma of the breast from remnants of the embryological ectodermal layer.

**Key words:** mammary gland; rhabdomyosarcoma; ectomesenchymoma; male; case report; CD99

Satală CB, Jung I, Bara TJ, Simu P, Simu I, Vlad M, Szodorai R, Gurzu S. Primary rhabdomyosarcoma: An extremely rare and aggressive variant of male breast cancer. *World J Clin Cases* 2020; 8(19): 4466-4474 URL: https://www.wjgnet.com/2307-8960/full/v8/i19/4466.htm DOI: https://dx.doi.org/10.12998/wjcc.v8.i19.4466

**Core Tip:** In this paper we presented an exceedingly rare and aggressive case of mammary rhabdomyosarcoma (RMS) in a male patient. We found no cases previously published in international journals, reporting an RMS with a peripheral neuroectodermal tumour-like ectomesenchymal component, namely neuroectodermal differentiation. The specific nature of the case was indicated by the presence of the ectomesenchymal component in the biopsy specimen, the case being firstly diagnosed as a tumour with neural differentiation. These findings emphasize the need for an attentive microscopic evaluation of mesenchymal tumours in the mammary region, to further confirm or infirm the presence of a second highly-malignant tumour population.

**INTRODUCTION**

Rhabdomyosarcoma (RMS) is a rare soft tissue tumour which represents less than 1% of all mesenchymal tumours. It mostly occurs in children and young adults between the ages of 15 and 24 years[1-3]. The most common histological variant, the alveolar subtype is found in children and the pleomorphic subtype predominates in older adults[3,4].

The majority of RMS cases affect the soft tissue of the head and neck (35%-40% of cases), followed by the genitourinary system (25%), trunk and extremities (with 20%)[3]. RMSs which occur in the mammary region are exceedingly rare, with less than 30 cases reported up to February 2020[2].

Independently by localization, the presence of a second phenotype within the RMS, with both rhabdomyoblasts and cells with ectodermic differentiation, defines malignant ectomesenchymoma (MEM)[5]. The origin of the second population is thought to be the migratory neural crest cells, embryologically derived from ectoderm, the outer layer of the embryo[5,6]. Limited data have been published regarding this dual tumour, with fewer than 20 cases having ever been reported in English-language journals[5], however, none of these were located in the mammary region.

In this paper, we present the case of a male patient, diagnosed with mammary gland RMS with ectomesenchymal differentiation, and we emphasize the complex immune profile needed for a positive and differential diagnosis. The signed, informed consent of the patient was obtained before surgery, for both surgical intervention and the publication of data.

**CASE PRESENTATION**

***Chief complaints***

A 55-year-old male presented with a painful, ulcerated tumour mass, located on the anterior thoracic wall in the left mammary region (Figure 1).

***History of present illness***

The patient reported a six month history of pain in the left mammary region, caused by a progressively growing, ulcerated tumour mass, with no other significant symptoms. Three months before presentation in our department, he underwent a biopsy and suspicion of a tumour of neural origin, namely a peripheral neuroectodermal tumour (PNET) was raised, based on the positivity of tumour cells for Neurofilament and neuron specific enolase (NSE) and negativity for Cytokeratin AE1/AE3.

***History of past illness***

He was an ex-smoker of seven years and a social drinker, with arterial hypertension and ischaemic heart disease, which were controlled by medication.

***Personal and family history***

No previous illnesses were declared and there was no family history of oncologic diseases.

***Physical examination***

The physical examination revealed an ulcerated tumour mass, with infiltrative aspect, occupying the left mammary region (Figure 1). No other signs or symptoms were observed.

***Laboratory examinations***

A mild elevation of serum level of alanine-aminotransferase (55.4 U/L; normal ranges 0-41 U/L), aspartate-aminotransferase (70.0 U/L; normal ranges 0-40 U/L) and gamma-glutamil-transpeptidase (130 U/L; normal ranges 0-71 U/L) was observed, without any other serological modifications.

***Imaging examinations***

The preoperative CT-scan revealed a 67 mm ×  74 mm × 80 mm nodular mass, located on the anterior thoracic wall, laterally from the sternum, with high density (40 UH) and multiple disseminated micro-calcifications. Direct spread in the soft tissues and tumour-induced costal erosions were also documented, along with axillary and subclavicular adenopathies. The third intercostal space was infiltrated, with no involvement of parietal or visceral pleura.

After surgery, the CT-scan showed a 28 mm × 135 mm (antero-posterior/Lateral-lateral) haematoma affecting the axillary region and intercostal muscles. No mediastinum involvement or suspicion of bone or lung metastases were highlighted.

***Gross and histopathological assessment of surgical specimens***

Grossing of the left mastectomy specimen showed a 67 mm × 74 mm × 80 mm tumour mass, located on the inner medial quadrant of the mammary gland, which was associated with a 33 mm × 30 mm ulceration of the skin (Figure 1). On section, it was observed as a poorly circumscribed, yellow-grey tumour mass, with small haemorrhagic areas, which infiltrated the deep soft tissues. The attached muscular components were also macroscopically involved, as were the rib fragments.

Under the microscope, the predominant component, which represented over 70% of the tumour mass, consisted of clusters of large, intensely pleomorphic (> 20 mitoses/high power field), elongated cells, with perivascular proliferation but not tumour emboli. Multinucleated cells were also visible. These large cells were admixed with small cells, with amphophilic and scanty cytoplasm and round to oval, centrally located nuclei. This component proved the formation of Homer-Wright-like rosettes, which were composed of specific circular strands of tumour cells with round-oval nuclei, surrounding fibrillary cores. The tumour exhibited an infiltrative growth pattern, with involvement of the subcutaneous tissue and the deep resection margins (Figure 2).

***Immunohistochemical profile of tumour cells***

Both tumour populations expressed vimentin and did not display positivity for the epithelial markers, such Cytokeratin AE1/AE3 and Cytokeratin 7 (Tables 1 and 2). In the predominant component, namely the large and pleomorphic cells, with a Ki67 proliferation index of over 90%, the rhabdoid differentiation was proved in terms of positivity for desmin, sarcomeric actin and myogenin (Figure 3). The tumour cells were not marked by the neural- (neurofilament, NSE), neuroendocrine- (synaptophysin, chromogranin), mesothelial- (calretinin) or vascular markers (CD31, CD34) and did not show a melanoma immunoprofile (negative for S100 and HMB45) (Table 2).

The second component, composed of small cells, showed a Ki67 index of around 40% and a PNET-like aspect. The immunoprofile was similar to those of cells identified in the biopsy specimens. In contrast with the predominant component, these cells showed focal positivity for neurofilament, NSE and CD99 (Figure 4), without rhabdoid differentiation. They did not express desmin, Smooth Muscle Actin (SMA), sarcomeric actin or myogenin (Table 2).

**FINAL DIAGNOSIS**

Based on the histological examination and immunohistochemical profile, the final diagnosis was high-grade mammary gland pleomorphic RMS with neuroectodermal/ectomesenchymal differentiation and deep positive resection margins.

**TREATMENT**

Based on the imagistic investigations, a radical mastectomy of the left breast was decided upon. The patient signed the informed consent prior to surgery. Following the correct preoperatory preparation, an elliptical incision was made, centred around the ulcerated tumour mass. As the soft tissues were deeply infiltrated, the detachment of the tumour block was carried out simultaneously with fragments of the directly infiltrated pectoral and intercostal muscles and partial resection of the tumour-invaded anterior costal arches of ribs III-IV. Then, an excision of the axillary lymph nodes was conducted and the surgical specimens were transported to the Department of Pathology for further examination.

**OUTCOME AND FOLLOW-UP**

One month after surgery, the patient presented in our centre, with local recurrence (Figure 1). As the lung and bone metastases were developed and following explanation of the further therapeutic regimen possibilities, he refused both postoperative oncologic treatment and tumour re-excision with surgical reconstruction.

Without any oncological treatment, the patient died three months after the mastectomy.

**DISCUSSION**

To the best of our knowledge, none of the 30 cases of breast RMS, which were previously published in existing English literature[2], were reported in males, despite the fact that the RMSs with other localizations, such as those of the head and neck region, are mostly found in men[6,7].

Although the RMS is a relatively classic malignancy, which can be identified by an experienced pathologist with Haematoxylin-Eosin and only confirmed by the immunohistochemical stains, its rare variants might induce challenges in daily practice. The most common histologic variants of RMS are the embryonal-, botryoid-, alveolar- and pleomorphic subtype[7,8], the latter also being the predominant component of our case. For the diagnosis of sarcomas with dual components, it is mandatory that the histological examination of tumour cells be completed by a large panel of immunohistochemical markers. It is necessary to rule out carcinomas, melanomas, lymphomas and other tumours with neural origin or neuroendocrine differentiation (Table 2).

As regards the genesis of RMS with dual components, it is known that during embryonic myogenesis[4,9-11], myoblasts become mitotically active, then they fuse to form myotubes, which are large elongated cells with abundant eosinophilic cytoplasm. These large cells form primordium of skeletal muscle fibresand can remain in different stages of development, being the key elements of a further malignant tumour[4,9-11]. In our case, within the predominant tumour component, large cells resemble the rhabdomyoblasts, which are formed in the early embryologic stage of myogenesis, with some of them also showing multinucleated aggregates.

Our case is of great interest, especially due to the presence of a second, minor cell population resembling MEM, besides the rhabdomyomatous differentiation. MEM, primarily known as gangliorhabdomyosarcoma, is defined as a mixed malignant tumour, one of the elements of which isthe RMS component[8,9]. It is included within the group of tumours with neuroectodermal differentiation, together with PNET/Ewing sarcomas. This tumour is an exceptional finding, as most of the previously reported cases were diagnosed in children[8,12,13]. The case described in this article was firstly diagnosed as a malignant tumour with neural differentiation, due to the predominance of a PNET-like component in the biopsy specimen.

The presence of the MEM component, in this case with an RMS phenotype, could be explained by the plasticity of the tumour cells, which might have allowed dedifferentiation. We have not been able to find any study to support this hypothesis, however, the prevalence of this phenomena, mostly in a young population, along with a first diagnosis of pure RMS, may be two plausible arguments which strengthen this theory[14,15]. Hence, further studies are needed to confirm/infirm this hypothesis. Another drawback is the lack of a complete microscopic analysis of the tumour mass, as can occur in biopsy specimens. In our case, besides the presence of small CD99 positive cells, admixed within a larger one, another indicator of a second component was the presence of Homer-Wright-like rosettes, composed of circular strands of tumour cells with round-oval nuclei, surrounding fibrillary cores. These are mostly characteristic of tumours with neural or ectodermal origins, as in cases of PNET[13].

Thus, in this case, the diagnosis was RMS with neuroectodermal differentiation. Besides the arguments favouring this diagnosis, there is a further hypothesis related to the specific topography of the tumour. Breast embryogenesis is intimately related to the presence of milk lines[16]. These structures emerge from its primordium, known as the mammary ridge, which represents microscopic thickenings of the ectodermal layer of the embryo. These start as microscopic conglomerates of ectodermic cells which migrate from the caudal region proximally, to their final location and to fully develop the mammary glands[13,16]. Taking into account these embryogenetic particularities, neuroectodermal differentiation can be present in the sarcomas of the mammary region more frequently than previously thought.

As the diagnosis of MEM is difficult to establish, little is known about its molecular pathways and therapeutic guidelines[3,8,12,13]. Radiotherapy with/without chemotherapy can be done before or after surgical excision[17]. Kawamoto *et al*[18] postulated that the evolution of patients with MEM mainly depends on the resectability of the tumor. These fact is also sustained by the study of Freitas *et al*[19] who demonstrated that incomplete resection of the tumor, such in the present case, is followed by recurrence even though the patients received chemotherapy too. Regarding the chemotherapeutic regimen, its choice primarily depends on the histologic type of the mesenchymal component of MEM. If the chemotherapy targets the mesenchymal RMS component, radiotherapy targets the second, minor population, with neuroectodermal differentiation. The decision of adding or not radiotherapy belongs to the oncologist and should take into account the extent of the neuroectodermal population. In this case, the irradiation dose can go up to 36-45 Gy[17]. In cases such as those presented in this paper, therapeutic regimen should be focused on the predominant component, which was the RMS[4,8,9,17].

We found only two previously published cases of MEM, one by Oppenheimer *et al*[14] who reported a case of a 17-mo-old boy with MEM of the left wrist, who was disease free, four years after diagnosis. The second case, published by Paikos *et al*[15] diagnosed a seven-year-old boy with a MEM of the orbit, who had no residual tumour cells after 15 mo of follow-up treatment. This good evolution can be explained by the patient’s age, as tumour cells are more chemosensitive when a patient is younger[14,15], but also by the pure form of these previously reported cases. On the other hand, in our patient, first diagnosis was established three months after occurrence of the tumour (based on the patient’s anamnesis) and another six months passed without any therapy, due to the patient’s refusal, since distant metastases occurred.

**CONCLUSION**

This case highlights the heterogeneity of sarcomas, which is not as common as in malignant tumours with epithelial origins. On the other hand, although RMS is known to display very aggressive behaviour, almost one year passed from diagnosis to distant metastases. Such cases, diagnosed at an early stage, might present a better prognosis. However, therapeutic guidelines should be more focused on malignancies with dual components.

**ACKNOWLEDGEMENTS**

The authors thanks to all colleagues involved in the management of this case. Academic Proofreading Services Ltd. did the English correction.

**REFERENCES**

1 **Audino AN**, Setty BA, Yeager ND. Rhabdomyosarcoma of the Breast in Adolescent and Young Adult (AYA) Women. *J Pediatr Hematol Oncol* 2017; **39**: 62-66 [PMID: 27879537 DOI: 10.1097/MPH.0000000000000710]

2 **Mance M**, Smuđ-Orehovec S, Vrbanović-Mijatović V, Mijatović D. Primary Alveolar Rhabdomyosarcoma of the Breast in a 17-Year-Old Girl. *JCO Oncol Pract* 2020; **16**: 93-95 [PMID: 31770055 DOI: 10.1200/JOP.19.00476]

3 **Parham DM**, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. *Adv Anat Pathol* 2013; **20**: 387-397 [PMID: 24113309 DOI: 10.1097/PAP.0b013e3182a92d0d]

4 **Ruiz-Mesa C**, Goldberg JM, Coronado Munoz AJ, Dumont SN, Trent JC. Rhabdomyosarcoma in adults: new perspectives on therapy. *Curr Treat Options Oncol* 2015; **16**: 27 [PMID: 25975442 DOI: 10.1007/s11864-015-0342-8]

5 **Dantonello TM**, Leuschner I, Vokuhl C, Gfroerer S, Schuck A, Kube S, Nathrath M, Bernbeck B, Kaatsch P, Pal N, Ljungman G, Bielack SS, Klingebiel T, Koscielniak E; CWS. Malignant ectomesenchymoma in children and adolescents: report from the Cooperative Weichteilsarkom Studiengruppe (CWS). *Pediatr Blood Cancer* 2013; **60**: 224-229 [PMID: 22535600 DOI: 10.1002/pbc.24174]

6 **Emami A,** Sepheri Z, Gordon JW, Ghavami S. Biologic and clinical aspects or rhabdomyhosarcoma. *Int J Basic Sci Med* 2017; **2**: 1-4 [DOI: 10.15171/ijbsm.2017.01]

7 **Shin J**, Kim HJ, Kim DY, Gong G, Cho KJ. Primary Rhabdomyosarcoma of the Breast: Study of Three Cases at One Institution with a Review of Primary Breast Sarcomas. *J Pathol Transl Med* 2019; **53**: 308-316 [PMID: 31370385 DOI: 10.4132/jptm.2019.07.22]

8 **Huang SC**, Alaggio R, Sung YS, Chen CL, Zhang L, Kao YC, Agaram NP, Wexler LH, Antonescu CR. Frequent HRAS Mutations in Malignant Ectomesenchymoma: Overlapping Genetic Abnormalities With Embryonal Rhabdomyosarcoma. *Am J Surg Pathol* 2016; **40**: 876-885 [PMID: 26872011 DOI: 10.1097/PAS.0000000000000612]

9 **Hajivassiliou CA**, Carachi R, Simpson E, Patrick WJ, Young DG. Ectomesenchymoma: one or two tumors? Case report and review of the literature. *J Pediatr Surg* 1997; **32**: 1351-1355 [PMID: 9314261 DOI: 10.1016/s0022-3468(97)90320-1]

10 National Comprehensive Cancer Network. [Accessed December 07, 2019] Soft tissue sarcoma (version 4. 2019). Available from: https://www.nccn.org/professionals/physician\_gls/pdf.sarcoma.pdf

11 **Davicioni E**, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. *Cancer Res* 2006; **66**: 6936-6946 [PMID: 16849537 DOI: 10.1158/0008-5472.CAN-05-4578]

12 **Howley S**, Stack D, Morris T, McDermott M, Capra M, Betts D, O'Sullivan MJ. Ectomesenchymoma with t(1;12)(p32;p13) evolving from embryonal rhabdomyosarcoma shows no rearrangement of ETV6. *Hum Pathol* 2012; **43**: 299-302 [PMID: 21803398 DOI: 10.1016/j.humpath.2011.03.010]

13 **Boudjemaa S**, Petit A. Malignant Ectomesenchymoma: A Potential Pitfall of Diagnosis in the Spectrum of Pediatric Small Blue Round Cell Tumors. *Appl Immunohistochem Mol Morphol* 2019; **27**: e63-e64 [PMID: 28968263 DOI: 10.1097/PAI.0000000000000584]

14 **Oppenheimer O**, Athanasian E, Meyers P, Antonescu CR, Gorlick R. Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature. *Int J Surg Pathol* 2005; **13**: 113-116 [PMID: 15735865 DOI: 10.1177/106689690501300117]

15 **Paikos P**, Papathanassiou M, Stefanaki K, Fotopoulou M, Grigorios S, Tzortzatou F. Malignant ectomesenchymoma of the orbit in a child: Case report and review of the literature. *Surv Ophthalmol* 2002; **47**: 368-374 [PMID: 12161212 DOI: 10.1016/s0039-6257(02)00313-2]

16 **Macias H**, Hinck L. Mammary gland development. *Wiley Interdiscip Rev Dev Biol* 2012; **1**: 533-557 [PMID: 22844349 DOI: 10.1002/wdev.35]

17 **Weiss E**, Albrecht CF, Herms J, Behnke-Mursch J, Pekrun A, Brockmann K, Hess CF. Malignant ectomesenchymoma of the cerebrum. Case report and discussion of therapeutic options. *Eur J Pediatr* 2005; **164**: 345-349 [PMID: 15747131 DOI: 10.1007/s00431-005-1646-7]

18 **Kawamoto EH**, Weidner N, Agostini RM Jr, Jaffe R. Malignant ectomesenchymoma of soft tissue. Report of two cases and review of the literature. *Cancer* 1987; **59**: 1791-1802 [PMID: 2950992 DOI: 10.1002/1097-0142(19870515)59:10<1791::aid-cncr2820591018>3.0.co;2-#]

19 **Freitas AB**, Aguiar PH, Miura FK, Yasuda A, Soglia J, Soglia F, Aguiar CH, Vinko F, Silva NS. Malignant ectomesenchymoma. Case report and review of the literature. *Pediatr Neurosurg* 1999; **30**: 320-330 [PMID: 10494059 DOI: 10.1159/000028818]

**Footnotes**

**Informed consent statement:** Signed consent of patient was obtained, before surgery.

**Conflict-of-interest statement:** None declared.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist statement and the manuscript was prepared and revised according to the CARE statement checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** May 24, 2020

**First decision:** July 25, 2020

**Article in press:** September 4, 2020

**Specialty type:** Andrology

**Country/Territory of origin:** Romania

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ribeiro MA **S-Editor:** Ma YJ **L-Editor:** A **P-Editor:** Xing YX

**Figure Legends**



**Figure 1 Macroscopic features.** A: Ulcerated rhabdomyosarcoma of the male breast; B: Tumor relapse, one month after mastectomy.



**Figure 2 Histological features of a hybrid tumor of the breast.** A and B: major population, some of the cells showing rhabdomyoblastic differentiation (A) and atypical mitoses (B); C-E: small cell population, demonstrating lobular architecture (C), with formation of rosette-like structures (D and E).



**Figure 3 Immunohistochemical profile of major cell population.** A: Vimentin diffuse positivity confirms the mesenchymal origin; B-D: the rhabdomyosarcomatous  differentiation is confirmed by the positivity for desmin (B), myogenin (C) and sarcomeric actin (D).



**Figure 4 Immunohistochemical profile of small cell population.** A-C: The neuroectodermal origin is confirmed by the positivity for neurofilament (A), neuron specific enolase (B) and CD99 (C); D: CD56 positivity proves the interaction between myocytes and neural cells.

**Table 1 Immunohistochemical markers used to confirm the rhabdomyosarcoma with neuroectodermal differentiation**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Antibody** | **Clone** | **Dilution** | **Manufacturer** | **Retrieval** | **RMS comp** | **NED comp** | **Line of differentiation confirmed** |
| VIM | V9 | RTU | DAKO/  Denmark | High pH | + | + | Mesenchymal origin |
| DESM | D33 | RTU | DAKO | High pH | + | - | Myogenic origin |
| MYO | F5D | 1:100 | ImmunoLogic/Netherland | High pH | + | - | Rhabdomyosarcoma component |
| SA | Alpha Sr-1 | 1:100 | DAKO | Citrate | + | - | Rhabdomyosarcoma component |
| NF | 2F11 | 1:100 | DAKO | Citrate | - | + | Neuroectodermal component |
| NSE | BBS/NC/V1-414 | RTU | DAKO | High pH | - | + | Neuroectodermal component |
| CD99 | 12E7 | RTU | DAKO | High pH | - | + | Neuroectodermal component |

Comp: component; DESM: desmin; MYO: myogenin; NED: neuroectodermal; NF: neurofilament; NSE: neuron specific enolase; SA: sarcomeric actin; RMS: rhabdomyosarcoma; RTU: ready to use; VIM: vimentin.

**Table 2 Immunohistochemical markers used for differential diagnosis of rhabdomyosarcoma with neuroectodermal differentiation, based on their negativity in the two components**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Antibody** | **Clone** | **Dilution** | **Manufacturer** | **Retrieval** | **Line of differentiation ruled out** |
| Pan-CK | AE1/AE3 | RTU | ImmunoLogic/  Netherland | High pH | Epithelial origin/carcinoma |
| EMA | E29 | RTU | ImmunoLogic | High pH |
| CK7 | OV-TL | RTU | A. Menarini/  Italy | High pH |
| p63 | 4A4 | RTU | ImmunoLogic | High pH | Squamous cell differentiation |
| SMA | 1A4 | RTU | Cell Marque/  Netherland | High pH | Leyomyosarcoma |
| CALd | 4-CD | 1:100 | DAKO/  Denmark | Citrate |
| CALr | DAK Calret-1 | 1:100 | DAKO | High pH | Mesothelial origin |
| ER | 1D5 | RTU | Thermo Scientific/UK | High pH | Breast carcinoma |
| PR | PGR 312 | RTU | Leica/UK | High pH |
| S100 protein | polyclonal | 1:6000 | DAKO | Citrate | Melanoma |
| HMB45 | HMB45 | RTU | Cell Marque | Citrate |
| CD45/  LCA | UCHL-1 | RTU | Immunologic | High pH | Lymphoma |
| CD3 | F7.2.38 | RTU | DAKO | High pH |
| CD20 | L26 | RTU | Cell Marque | High pH |
| CD31 | JC70 | RTU | A. Menarini | Citrate | Vascular origin |
| CD34 | QBEnd10 | RTU | DAKO | High pH |
| CD68 | KP1 | RTU | Immunologic | Citrate | Histiocytic origin |
| SYN | DAK-Synap | RTU | DAKO | High pH | Neuroendocrine differentiation |

CALd: caldesmon; CALr: calretinin; CK: cytokeratin; EMA: epithelial membrane antigen; ER: estrogen receptor; HMB45: human melanoma black 45; LCA: leukocyte common antigen; PR: progesteron receptor; RTU: ready to use; SMA: smooth muscle actin; SYN: synaptophysin.